Literature DB >> 15831617

Gentamicin induced ototoxicity during treatment of enterococcal endocarditis: resolution with substitution by netilmicin.

J E East1, J E Foweraker, F D Murgatroyd.   

Abstract

Enterococcal endocarditis can be very difficult to eradicate, requiring prolonged treatment with a combination of a penicillin and an aminoglycoside. In this patient with a pacemaker associated enterococcal endocarditis, ototoxicity occurred due to total gentamicin dose despite plasma concentrations consistently within the treatment range. Substitution with netilmicin, without a break in aminoglycoside treatment, resulted in a rapid improvement in hearing and allowed the required course of aminoglycoside to be completed. The risk factors for ototoxicity with gentamicin are reviewed, in particular the dangers of increasing age and of multiple and prolonged courses. Close treatment monitoring does not totally avoid this risk, especially when prolonged aminoglycoside treatment is required. This case emphasises the need for prompt investigation and adequate, definitive treatment of enterococcal endocarditis to avoid the increased risk consequent on repeated courses of antibiotics. The resolution of the ototoxicity with netilmicin is consistent with other reports of lower cochleotoxicity than with other aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831617      PMCID: PMC1768868          DOI: 10.1136/hrt.2003.028308

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

1.  Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis. Working Party of the British Society for Antimicrobial Chemotherapy.

Authors: 
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

2.  Ototoxicity induced by once-daily gentamicin.

Authors:  F El Bakri; A Pallett; A G Smith; A S Duncombe
Journal:  Lancet       Date:  1998-05-09       Impact factor: 79.321

3.  Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used?

Authors:  Lars Olaison; Kimmo Schadewitz
Journal:  Clin Infect Dis       Date:  2001-12-07       Impact factor: 9.079

Review 4.  Aminoglycoside-induced ototoxicity.

Authors:  P J Govaerts; J Claes; P H van de Heyning; P G Jorens; J Marquet; M E De Broe
Journal:  Toxicol Lett       Date:  1990-08       Impact factor: 4.372

5.  Ototoxicity induced by gentamicin and furosemide.

Authors:  Duane E Bates; Steve J Beaumont; Barry W Baylis
Journal:  Ann Pharmacother       Date:  2002-03       Impact factor: 3.154

6.  Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association.

Authors:  W R Wilson; A W Karchmer; A S Dajani; K A Taubert; A Bayer; D Kaye; A L Bisno; P Ferrieri; S T Shulman; D T Durack
Journal:  JAMA       Date:  1995-12-06       Impact factor: 56.272

7.  Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-01       Impact factor: 5.226

Review 8.  Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.

Authors:  G Kahlmeter; J I Dahlager
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

Review 9.  Determinants of efficacy and toxicity of aminoglycosides.

Authors:  H Mattie; W A Craig; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

  9 in total
  2 in total

1.  Interaction of gentamicin with phosphatidylserine/phosphatidylcholine mixtures in adsorption monolayers and thin liquid films: morphology and thermodynamic properties.

Authors:  Georgi D Georgiev; Georgi As Georgiev; Z Lalchev
Journal:  Eur Biophys J       Date:  2010-03-04       Impact factor: 1.733

2.  Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials.

Authors:  Moritz Mirna; Albert Topf; Lukas Schmutzler; Uta C Hoppe; Michael Lichtenauer
Journal:  Clin Res Cardiol       Date:  2021-11-09       Impact factor: 6.138

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.